All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2026-11-02.
From the record
Kazia Therapeutics Limited's filings since 2017 show 3 warning events: a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2026-11-02) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-22.3% a year over 6 filed years; profitable in 0 of 9.
From the record
Kazia Therapeutics Limited's 6 filed years say what it did: revenue went from AUD 406 thousand in fiscal 2016 to AUD 42 thousand in fiscal 2025, down 22.3% a year; it rose in 0 of 4 years; the deepest fall was 100% from fiscal 2016 to fiscal 2023; net income was positive in 0 of 9 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Kazia Therapeutics Limited's shareholder treatment is put at 2.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 29% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 237%: owes 237¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-06-30, Kazia Therapeutics Limited's shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 237 cents per dollar of assets, and net share issuance: its share count grew 107.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 14% of 315 in its family; net margin -49290.5%.
From the record
Kazia Therapeutics Limited's standing among 315 graded names in its industry family: revenue of AUD 42 thousand in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -49290.5% ranks in the bottom 4%; revenue growth of -13.8% a year over the last 3 filed years ranks in the bottom 24% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Kazia Therapeutics Limited's leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 41% of 273 in its family for room to expand.
From the record
Kazia Therapeutics Limited's room to grow, from the newest filed statements (fiscal 2025): cash of AUD 4 million against no long-term debt tagged leaves 71.7% of its assets as net cash, top 22% of its family; cash from operations less capital spending is -31614.3% of revenue (bottom 4%); research spending of 17442.9% of revenue (top 4%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 24% of 306 in its family for growth drivers.
From the record
Kazia Therapeutics Limited's growth drivers, from the filed years to fiscal 2025: revenue grew -13.8% a year over the last three filed years against -22.3% over all 6, speeding up (top 19% of its family); the newest year grew -98.2% (bottom 2%); research spending grew -28.6% a year (bottom 13%); capital spending grew -97.7% a year (bottom 1%) (its annual reports). Kazia Therapeutics Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 25% of 233 in its family for expectations against reality.
From the record
Kazia Therapeutics Limited's newest year against its own record: revenue of AUD 42 thousand in fiscal 2025 came in 98.9% below the AUD 4 million its prior three years' pace pointed to (bottom 1% of its family); net income of AUD 21 million against a prior three-year average of AUD 24 million (bottom 48%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made